LBT Innovations Ltd (ASX: LBT) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

LBT Innovations Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $22.79 million
P/E Ratio N/A
Dividend Yield 0.00%
Shares Outstanding 1.34 billion
Earnings per share -0.045
Dividend per share N/A
Year To Date Return 45.45%
Earnings Yield N/A
Franking -
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • LBT Innovations Ltd (ASX: LBT)
    Latest News

    A young woman with her mouth open and her hands out showing surprise and delight as uranium share prices skyrocket
    Healthcare Shares

    Guess which ASX AI stock rocketed 170% on an AstraZeneca update

    Investors are loving this company's announcement on Wednesday.

    Read more »

    doctor looks out window resting head in hand
    Healthcare Shares

    LBT Innovations (ASX:LBT) share price plummets 14% despite positive update

    The company's shares are off to a bad start this week...

    Read more »

    Healthcare Shares

    Why the LBT Innovations share price is charging higher today

    The LBT Innovations Limited (ASX: LBT) share price is storming higher today after the company announced the first sale of…

    Read more »

    a woman
    Speculative

    Why the LBT Innovations share price rocketed 243% higher on Tuesday

    The LBT Innovations Limited (ASX:LBT) share price was an impressive performer on Tuesday, rising a staggering 243% at one stage...

    Read more »

    a woman
    ⏸️ Investing

    3 fast-growing biotech shares at the top of my watch list

    CSL Limited (ASX:CSL) is the king of biotech shares, but could one of these three fledgling biotechs one day sit…

    Read more »

    a woman
    ⏸️ Investing

    Here's why LBT Innovations Limited shares rocketed 89% today

    LBT Innovations Limited (ASX:LBT) shares are soaring after gaining FDA approval for its Automated Plate Assessment System. But is it…

    Read more »

    ⏸️ Investing

    What investors can learn from LBT Innovations Limited's slump to a seven-month low

    LBT Innovations Limited's (ASX:LBT) painful crash today on news that its French partner is pursuing another interest holds lessons for…

    Read more »

    a woman
    ⏸️ Investing

    4 stocks that soared more than 16% today

    A fall in the ASX index today couldn't spoil these four stocks' day in the sun

    Read more »

    LBT ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About LBT Innovations Ltd

    LBT Innovations Ltd is a designer of advanced technology solutions for the medical industry. Its first product, MicroStreak, was a global first in the automation of the culture plate streaking process. Its second product, the Automated Plate Assessment System(APAS) is based upon LBT's intelligent imaging and machine learning software and remains the only US FDA-cleared artificial intelligence technology for automated imaging, analysis, and interpretation of microbiology culture plates following incubation.

    LBT Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    20 May 2024 $0.02 $0.00 0.00% 679,243 $0.02 $0.02 $0.02
    17 May 2024 $0.02 $0.00 0.00% 526,316 $0.02 $0.02 $0.02
    16 May 2024 $0.02 $0.00 0.00% 155,898 $0.02 $0.02 $0.02
    15 May 2024 $0.02 $0.00 0.00% 742,921 $0.02 $0.02 $0.02
    14 May 2024 $0.02 $0.00 0.00% 1,364,545 $0.02 $0.02 $0.02
    13 May 2024 $0.02 $0.00 0.00% 170,941 $0.02 $0.02 $0.02
    10 May 2024 $0.02 $0.00 0.00% 163,940 $0.02 $0.02 $0.02
    09 May 2024 $0.02 $0.00 0.00% 2,071,246 $0.02 $0.02 $0.02
    08 May 2024 $0.02 $0.00 0.00% 93,675 $0.02 $0.02 $0.02
    07 May 2024 $0.02 $0.00 0.00% 662,610 $0.02 $0.02 $0.02
    06 May 2024 $0.02 $0.00 0.00% 85,619 $0.02 $0.02 $0.02
    03 May 2024 $0.02 $0.00 0.00% 630,002 $0.02 $0.02 $0.02
    02 May 2024 $0.02 $0.00 0.00% 1,107,767 $0.02 $0.02 $0.02
    01 May 2024 $0.02 $0.00 0.00% 729,226 $0.02 $0.02 $0.02
    30 Apr 2024 $0.02 $0.00 0.00% 371,611 $0.02 $0.02 $0.02
    29 Apr 2024 $0.02 $0.00 0.00% 5,587,236 $0.02 $0.02 $0.02
    26 Apr 2024 $0.02 $0.00 0.00% 68,000 $0.02 $0.02 $0.02
    24 Apr 2024 $0.02 $0.00 0.00% 937,939 $0.02 $0.02 $0.02
    23 Apr 2024 $0.02 $0.00 0.00% 1,888,949 $0.02 $0.02 $0.02

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    19 Dec 2023 Rebecca Wilson Issued 1,250,000 $15,000
    Director remuneration.
    19 Dec 2023 Brenton Barnes Issued 1,031,250 $24,750
    Director remuneration. VWAP
    19 Dec 2023 Brian O'Dwyer Issued 524,379 $31,500
    Director remuneration. VWAP
    15 Nov 2023 Brenton Barnes Issued 70,000,000 $280,000
    Rights issue.
    15 Nov 2023 Brenton Barnes Issued 50,000,000 $250,000
    Rights issue.
    15 Nov 2023 Brenton Barnes Issued 20,000,000 $100,000
    Rights issue.
    15 Nov 2023 Damian Lismore Transfer 539,494 $2,157
    Off-market transfer. Assuming off - market transfer of shares
    15 Nov 2023 Damian Lismore Transfer 539,494 $2,157
    Off-market transfer. Assuming off - market transfer of shares
    15 Nov 2023 Damian Lismore Issued 4,160,000 $16,640
    Rights issue. There is typo error for post holding
    15 Nov 2023 Damian Lismore Issued 4,160,000 $20,800
    Rights issue.
    15 Nov 2023 Rebecca Wilson Issued 13,597,400 $67,987
    Rights issue.
    15 Nov 2023 Rebecca Wilson Issued 13,597,400 $54,389
    Rights issue.

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Ms Rebecca Wilson Non-Executive Director Jul 2023
    --
    Mr Brenton John Barnes Chief Executive OfficerManaging Director Aug 2016
    Mr Barnes becoming the second CEO of the company and taking over from the founder. Since joining, Brent has focused on building internal capability across scientific, artificial intelligence and engineering disciplines that maximise the development opportunities of the machine vision intellectual property generated by the company. This strategy facilitated the development of LBT's flagship product APAS Independence, enabling the company to transition to a sales and commercialisation focus. Brent brings a big company vision with a global outlook to LBT.
    Mr Brian O'Dwyer Non-Executive Director Oct 2021
    Mr O'Dwyer has more than 20 years of experience in the healthcare and laboratory testing industry. He is currently the Chief Executive Officer of Q2 Solutions, a leading clinical trials laboratory testing organisation and subsidiary of IQVIA (NYSE: IQV), a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry. Having previously held a number of senior roles at Eurofins Central Laboratory and ICON Plc, Brian brings deep industry knowledge and expertise in laboratory testing businesses to the Board. His experience spans across the establishment, management, integration and restructuring of both business and commercial operations through the clinical research spectrum. Brian strengthens the Board's skillset with strategic planning, business strategy and leadership skills.
    Mr Daniel (Dan) Hill Non-Executive Director Dec 2023
    Mr Hill is Adelaide based and brings extensive commercial experience to the Company as both a successful investor and
    business owner. He became a substantial Shareholder after participating as a cornerstone sub-underwriter in the Company's
    recent Entitlement Offer. With a background in finance, as well as being an experienced Company Director, he will bring a
    focus on business growth and commercial strategy to the Company.
    Mr Ray Ridge Chief Financial OfficerCompany Secretary Feb 2020
    -
    Ray Ridge Chief Financial OfficerCompany Secretary
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    Hettich Holding Beteiligungs-Und Verwaltungs-Gmbh\C 30,660,377 8.64%
    Citicorp Nominees Pty Limited 14,048,544 3.96%
    Biomerieux Sa\C 9,772,727 2.76%
    B Moran Pty Ltd 8,621,458 2.43%
    Z & F International Trading Limited 6,451,613 1.82%
    Kew Superannuation Fund Pty Ltd <K W Superannuation Fund A/C> 6,000,000 1.69%
    Mazoni Pty Ltd <The Utiger Super Fund A/C> 6,000,000 1.69%
    Mr Robert Andrew Finder & Mrs Sheryl Jean Finder <Sherrob9 S/F A/C> 5,401,665 1.52%
    Dr Russell Kay Hancock 5,000,000 1.41%
    Rje Aerospace Pty Ltd <Equid Super A/C> 4,117,366 1.16%
    Matandren Pty Ltd <Burgess Tate A/C> 3,686,476 1.04%
    Bearay Pty Ltd <Brian Clayton S/F A/C> 3,573,537 1.01%
    Mr Stephen Goodwin 3,500,000 0.99%
    Colonial First State Inv Ltd <12543782 D Mckay A/C> 3,456,632 0.97%
    Mr Hugh Berkeley Guthrie & Mrs Lucyna Halina Guthrie <Podlaska Super A/C> 3,302,988 0.93%
    Dr Jiansheng Zhou 3,052,742 0.86%
    Ruin Pty Ltd <Steve Mathwin Super A/C> 3,005,262 0.85%
    Chag Pty Ltd 3,000,000 0.85%
    Mr Bryan Pliatsios 2,639,151 0.74%
    Mr Richard Anthony Earp 2,557,500 0.72%

    Profile

    since

    Note